{"disease":{"id":"pyruvate-kinase-deficiency","name":"pyruvate kinase deficiency"},"drugs":{"marketed":[{"drug_id":"mitapivat","indication_name":"Pyruvate kinase (PK) deficiency","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pyrukynd","generic_name":"MITAPIVAT","company_name":"Agios Pharms Inc","drug_phase":"marketed","molecular_target":"Pyruvate kinase PKLR","drug_class":"Pyruvate Kinase Activator [EPC]","quality_score":65,"revenue":null,"mechanism":"Pyrukynd works by activating the pyruvate kinase PKLR enzyme to improve energy production in red blood cells."}],"pipeline":[],"offLabel":[],"totalMarketed":1,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT03481738","title":"Pyruvate Kinase Deficiency Global Longitudinal Registry","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":500,"lead_sponsor_name":"Agios Pharmaceuticals, Inc.","has_results":false},{"nct_id":"NCT04902833","title":"Acquired Pyruvate Kinase Deficiency In Clonal Myeloid Neoplasms","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":100,"lead_sponsor_name":"Massachusetts General Hospital","has_results":false},{"nct_id":"NCT03853798","title":"Extension Study of AG-348 in Adult Participants With Pyruvate Kinase Deficiency Previously Enrolled in AG-348-006 or AG348-C-007","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":90,"lead_sponsor_name":"Agios Pharmaceuticals, Inc.","has_results":true},{"nct_id":"NCT03548220","title":"A Study to Evaluate Efficacy and Safety of AG-348 in Not Regularly Transfused Adult Participants With Pyruvate Kinase Deficiency (PKD)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":80,"lead_sponsor_name":"Agios Pharmaceuticals, Inc.","has_results":true},{"nct_id":"NCT03866590","title":"Pyruvate Kinase Deficiency Epidemiological Study (PIECE)","phase":"","overall_status":"COMPLETED","enrollment_count":75,"lead_sponsor_name":"CENTOGENE GmbH Rostock","has_results":false},{"nct_id":"NCT02476916","title":"A Study of AG-348 in Adult Participants With Pyruvate Kinase (PK) Deficiency","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":52,"lead_sponsor_name":"Agios Pharmaceuticals, Inc.","has_results":true},{"nct_id":"NCT03559699","title":"A Study Evaluating the Efficacy and Safety of AG-348 in Regularly Transfused Adult Participants With Pyruvate Kinase Deficiency (PKD)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":27,"lead_sponsor_name":"Agios Pharmaceuticals, Inc.","has_results":true},{"nct_id":"NCT04964323","title":"Pyruvate Kinase (PK) Deficiency Global Longitudinal Registry: Patient-Reported Outcomes (PRO)","phase":"","overall_status":"TERMINATED","enrollment_count":15,"lead_sponsor_name":"Agios Pharmaceuticals, Inc.","has_results":false},{"nct_id":"NCT04995315","title":"Pyruvate Kinase Deficiency Global Longitudinal Registry Substudy of Protocol AG348-C-008","phase":"","overall_status":"COMPLETED","enrollment_count":13,"lead_sponsor_name":"Agios Pharmaceuticals, Inc.","has_results":false},{"nct_id":"NCT04105166","title":"Gene Therapy for Pyruvate Kinase Deficiency (PKD)","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":4,"lead_sponsor_name":"Rocket Pharmaceuticals Inc.","has_results":false}],"total":10},"guidelines":[],"source":"Drug Landscape verified database"}